MT 301
Alternative Names: MT-301Latest Information Update: 06 Feb 2024
At a glance
- Originator Myeloid Therapeutics
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 01 Feb 2024 Myeloid Therapeutics plans a clinical trial for Liver cancer (IV)
- 19 May 2022 Myeloid Therapeutics in-licenses lipid nanoparticle (LNP) technology from Acuitas Therapeutics
- 24 Apr 2022 Pharmacodynamics data from a preclinical studies in cancer presented at 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)(Myeloid Therapeutics website, April 2022)